JP2014076962A - 脂肪肝抑制剤 - Google Patents
脂肪肝抑制剤 Download PDFInfo
- Publication number
- JP2014076962A JP2014076962A JP2012225455A JP2012225455A JP2014076962A JP 2014076962 A JP2014076962 A JP 2014076962A JP 2012225455 A JP2012225455 A JP 2012225455A JP 2012225455 A JP2012225455 A JP 2012225455A JP 2014076962 A JP2014076962 A JP 2014076962A
- Authority
- JP
- Japan
- Prior art keywords
- fatty liver
- liver
- extract
- fructose
- root
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000004930 Fatty Liver Diseases 0.000 title claims abstract description 53
- 206010019708 Hepatic steatosis Diseases 0.000 title claims abstract description 53
- 208000010706 fatty liver disease Diseases 0.000 title claims abstract description 53
- 231100000240 steatosis hepatitis Toxicity 0.000 title claims abstract description 53
- 239000003112 inhibitor Substances 0.000 title claims abstract description 17
- 239000000284 extract Substances 0.000 claims abstract description 58
- 239000004480 active ingredient Substances 0.000 claims abstract description 7
- AEDDIBAIWPIIBD-ZJKJAXBQSA-N mangiferin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=C(OC=2C(=CC(O)=C(O)C=2)C2=O)C2=C1O AEDDIBAIWPIIBD-ZJKJAXBQSA-N 0.000 claims description 60
- 244000272911 Salacia chinensis Species 0.000 claims description 31
- YWQSXCGKJDUYTL-UHFFFAOYSA-N Mangiferin Natural products CC(CCC=C(C)C)C1CC(C)C2C3CCC4C(C)(C)CCCC45CC35CCC12C YWQSXCGKJDUYTL-UHFFFAOYSA-N 0.000 claims description 30
- 229940043357 mangiferin Drugs 0.000 claims description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 23
- 241000647991 Salacia reticulata Species 0.000 claims description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- 239000003125 aqueous solvent Substances 0.000 claims description 7
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 4
- 241000545263 Salacia <hydroid> Species 0.000 abstract description 6
- 230000003203 everyday effect Effects 0.000 abstract description 2
- 244000087020 Salacia prinoides Species 0.000 abstract 1
- 239000005715 Fructose Substances 0.000 description 40
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 40
- 229930091371 Fructose Natural products 0.000 description 40
- 210000004185 liver Anatomy 0.000 description 34
- 230000037396 body weight Effects 0.000 description 20
- 230000000694 effects Effects 0.000 description 19
- 238000000605 extraction Methods 0.000 description 18
- 241000700159 Rattus Species 0.000 description 14
- 239000003814 drug Substances 0.000 description 13
- 239000002904 solvent Substances 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 210000005228 liver tissue Anatomy 0.000 description 12
- 229940079593 drug Drugs 0.000 description 10
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 9
- 229960002297 fenofibrate Drugs 0.000 description 9
- 230000007935 neutral effect Effects 0.000 description 9
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 238000001035 drying Methods 0.000 description 8
- 235000021050 feed intake Nutrition 0.000 description 8
- 241000196324 Embryophyta Species 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 238000012353 t test Methods 0.000 description 7
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 5
- 239000003524 antilipemic agent Substances 0.000 description 5
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000009395 breeding Methods 0.000 description 4
- 230000001488 breeding effect Effects 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 208000006454 hepatitis Diseases 0.000 description 4
- 231100000283 hepatitis Toxicity 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 241000134253 Lanka Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 102000012141 Peroxisome proliferator-activated receptor alpha Human genes 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000002354 daily effect Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 3
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 description 3
- 230000003449 preventive effect Effects 0.000 description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 206010020880 Hypertrophy Diseases 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- -1 auxiliaries Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 235000006694 eating habits Nutrition 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 1
- 240000002234 Allium sativum Species 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010060891 General symptom Diseases 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010019728 Hepatitis alcoholic Diseases 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 206010019842 Hepatomegaly Diseases 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 102100024295 Maltase-glucoamylase Human genes 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- 201000002451 Overnutrition Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 208000002353 alcoholic hepatitis Diseases 0.000 description 1
- 108010028144 alpha-Glucosidases Proteins 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- OZECDDHOAMNMQI-UHFFFAOYSA-H cerium(3+);trisulfate Chemical compound [Ce+3].[Ce+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O OZECDDHOAMNMQI-UHFFFAOYSA-H 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000004611 garlic Nutrition 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- XELZGAJCZANUQH-UHFFFAOYSA-N methyl 1-acetylthieno[3,2-c]pyrazole-5-carboxylate Chemical compound CC(=O)N1N=CC2=C1C=C(C(=O)OC)S2 XELZGAJCZANUQH-UHFFFAOYSA-N 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 235000020830 overeating Nutrition 0.000 description 1
- 235000020823 overnutrition Nutrition 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229960001866 silicon dioxide Drugs 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
【解決手段】本発明に係る脂肪肝抑制剤は、サラシア・レティキュラータおよびサラシア・キネンシスから選択される少なくとも一方の根部の抽出物を有効成分として含むことを特徴とする。
【選択図】なし
Description
平成22年にインド最南部東側のタミールナダで自生しているサラシア・レティキュラータ(SR)を採取し、自然乾燥させておいた。その根部1.0kgを粗切りし、熱水10Lに入れ、3時間加熱した。次いで、濾過して粗切根部を分離し、再度同様の抽出操作に付し、抽出液を得た。抽出液を合わせ、45℃以下で減圧濃縮し、SR根部抽出物を69g得た。抽出収率は約7%であった。
タイ東北部のコンケンで自生しているサラシア・キネンシス(SC)を平成22年に採取して用いた以外は実施例1と同様にして、SC根部抽出物を70g(抽出収率:約7%)得た。
体重210〜230gの雄性Sprague−Dawleyラット(以下、「SDラット」という)を、室温21±1℃、湿度55±5%の12時間毎、明暗の飼育室で自由に飼料と水を摂取させ、1週間予備飼育した。
上記実施例3の結果のとおり、SRおよびSCの根部抽出物にそれぞれ果糖誘発脂肪肝に対する有効性が認められたので、SC根部抽出物を分画し、同様の測定を行った。具体的には、実施例2で得られたSC根部抽出物(50g)を、カラムクロマトグラフィー(GEヘルスケア社製,Sephadex LH−20)を用い、水100%溶出部、水:メタノール=50:50溶出部、メタノール100%溶出部の三分画に分離した。以下、各分画をそれぞれSC分画1〜3という。また、各分画の収量は、SC根部抽出物50gに対してそれぞれ32g、6.5g、6.8gであった。
上記実施例4のとおり、SC抽出物分画3に脂肪肝の改善効果が著明に認められたので、SC抽出物分画3の成分を分析した。
上記実施例2において、抽出溶媒を水から50v/v%メタノール水に変更した以外は同様にしてSC根部抽出物を得、その急性毒性について検討した。詳しくは、体重20g前後のDD−Y系雄性マウス8匹に、当該抽出物を物理的に経口投与可能な2,000mg/kgの割合で1回投与し、水と通常飼料を自由摂取させつつ1週間飼育した。
Claims (6)
- サラシア・レティキュラータおよびサラシア・キネンシスから選択される少なくとも一方の根部の抽出物を有効成分として含むことを特徴とする脂肪肝抑制剤。
- 上記抽出物が水系溶媒による抽出物である請求項1に記載の脂肪肝抑制剤。
- 上記水系溶媒が、水およびC1-4アルコールから選択される少なくとも1種である請求項2に記載の脂肪肝抑制剤。
- 上記抽出物が、水系溶媒抽出物のメタノール可溶分である請求項2または3に記載の脂肪肝抑制剤。
- 上記抽出物がマンギフェリンを0.5質量%以上含むものである請求項1〜4のいずれかに記載の脂肪肝抑制剤。
- 脂肪肝が非アルコール性脂肪肝である請求項1〜5のいずれかに記載の脂肪肝抑制剤。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2012225455A JP6101888B2 (ja) | 2012-10-10 | 2012-10-10 | 脂肪肝抑制剤 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2012225455A JP6101888B2 (ja) | 2012-10-10 | 2012-10-10 | 脂肪肝抑制剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2014076962A true JP2014076962A (ja) | 2014-05-01 |
JP6101888B2 JP6101888B2 (ja) | 2017-03-29 |
Family
ID=50782593
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012225455A Active JP6101888B2 (ja) | 2012-10-10 | 2012-10-10 | 脂肪肝抑制剤 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP6101888B2 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6145552B1 (ja) * | 2016-11-18 | 2017-06-14 | 正則 那須 | 脂肪肝治療用組成物 |
CN115137773A (zh) * | 2022-08-09 | 2022-10-04 | 劲牌有限公司 | 一种抑制胰脂肪酶的降脂中药组合物及其制备方法 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002020302A (ja) * | 2000-07-06 | 2002-01-23 | Morishita Jintan Kk | 抗酸化作用を有する肝保護剤 |
JP2002267655A (ja) * | 2001-03-08 | 2002-09-18 | Morishita Jintan Kk | ニシキギ科サラキア属の植物および/またはそれからの抽出物の品質判定方法 |
JP2003245095A (ja) * | 2002-02-25 | 2003-09-02 | Sakamoto Yakusoen:Kk | サラシア属植物の生薬活性評価法 |
JP2005021006A (ja) * | 2003-06-30 | 2005-01-27 | Bc:Kk | アルコールによる影響を短時間で解消する飲食品用材料、飲食品、及び解毒剤 |
JP2009001540A (ja) * | 2007-05-22 | 2009-01-08 | Sakamoto Yakusoen:Kk | 心疾患抑制剤 |
JP2009077696A (ja) * | 2007-09-06 | 2009-04-16 | Fujifilm Corp | サラシア属植物の抽出物とフラボノイドを含有する食品 |
-
2012
- 2012-10-10 JP JP2012225455A patent/JP6101888B2/ja active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002020302A (ja) * | 2000-07-06 | 2002-01-23 | Morishita Jintan Kk | 抗酸化作用を有する肝保護剤 |
JP2002267655A (ja) * | 2001-03-08 | 2002-09-18 | Morishita Jintan Kk | ニシキギ科サラキア属の植物および/またはそれからの抽出物の品質判定方法 |
JP2003245095A (ja) * | 2002-02-25 | 2003-09-02 | Sakamoto Yakusoen:Kk | サラシア属植物の生薬活性評価法 |
JP2005021006A (ja) * | 2003-06-30 | 2005-01-27 | Bc:Kk | アルコールによる影響を短時間で解消する飲食品用材料、飲食品、及び解毒剤 |
JP2009001540A (ja) * | 2007-05-22 | 2009-01-08 | Sakamoto Yakusoen:Kk | 心疾患抑制剤 |
JP2009077696A (ja) * | 2007-09-06 | 2009-04-16 | Fujifilm Corp | サラシア属植物の抽出物とフラボノイドを含有する食品 |
Non-Patent Citations (2)
Title |
---|
JPN6013056236; WATANABE Michiru et al: 'Preventive effects of Salacia reticulata on non-alcoholic fatty liver disease (NAFLD)/ non-alcoholic' J Tradit Med Vol.28,No.2, 20110430, Page.73-82 * |
JPN6013056237; Hsun-Wei Huang et al: 'Salacia oblonga root improves postprandial hyperlipidemia and hepatic steatosis in Zucker diabetic f' Toxicology and Applied Pharmacology 210(3), 2006, pp.225-235 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6145552B1 (ja) * | 2016-11-18 | 2017-06-14 | 正則 那須 | 脂肪肝治療用組成物 |
WO2018092654A1 (ja) * | 2016-11-18 | 2018-05-24 | 正則 那須 | 脂肪肝治療用組成物 |
CN109996552A (zh) * | 2016-11-18 | 2019-07-09 | 那须正则 | 脂肪肝治疗用组合物 |
US10849950B2 (en) | 2016-11-18 | 2020-12-01 | Masanori NASU | Composition for treating fatty liver |
CN115137773A (zh) * | 2022-08-09 | 2022-10-04 | 劲牌有限公司 | 一种抑制胰脂肪酶的降脂中药组合物及其制备方法 |
CN115137773B (zh) * | 2022-08-09 | 2023-11-17 | 劲牌有限公司 | 一种抑制胰脂肪酶的降脂中药组合物及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
JP6101888B2 (ja) | 2017-03-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Atanu et al. | A review of the pharmacological aspects of Solanum nigrum Linn | |
Ashoush et al. | Antioxidant activity and hepatoprotective effect of pomegranate peel and whey powders in rats | |
Lin et al. | Chemopreventive properties and molecular mechanisms of the bioactive compounds in Hibiscus sabdariffa Linne | |
KR101501433B1 (ko) | 비알코올성 지방간 질환의 예방 및 치료용 조성물 | |
JPWO2009054504A1 (ja) | ペルオキシソーム増殖剤応答性受容体(ppar)のリガンド剤 | |
JP2006328056A (ja) | 肥満防止剤 | |
KR20130020095A (ko) | 멀꿀 추출물을 포함하는 간 보호용 조성물 | |
RU2701567C1 (ru) | Средство, обладающее гепатопротекторной активностью | |
JP2008214191A (ja) | 肝中脂質蓄積抑制剤 | |
JP6101888B2 (ja) | 脂肪肝抑制剤 | |
Chiang et al. | Active food ingredients production from cold pressed processing residues of Camellia oleifera and Camellia sinensis seeds for regulation of blood pressure and vascular function | |
Gaafar et al. | Hypoglycemic effects of white cabbage and red cabbage (Brassica oleracea) in STZ induced type-2 diabetes in rats | |
KR102188238B1 (ko) | 당귀 추출물, 천궁 추출물 및 작약 추출물을 포함하는 피로 회복 또는 운동 수행능력 증진용 조성물 | |
KR20150053321A (ko) | 검정콩 껍질 유래의 안토시아닌을 유효성분으로 함유하는 항비만 조성물 | |
KR101887764B1 (ko) | 항비만성 팥 껍질 추출물의 추출방법 및 이를 유효성분으로 함유하는 항비만 조성물 | |
KR20100002658A (ko) | 비만 치료 및 예방용 조성물과 기능성 식품 | |
CN110693873B (zh) | 冬凌草活性成分组合物的制备及应用 | |
KR101886299B1 (ko) | 도화 및 하엽 복합 추출물을 포함하는 비만 및 대사성 질환의 예방, 개선 또는 치료용 조성물 | |
EP3858370A1 (en) | Composition for alleviating fatigue or enhancing exercise capability comprising angelica gigas extract, cnidii rhizoma extract, and paeonia japonica extract | |
KR20100064816A (ko) | 고지혈증 치료시 유발되는 간 손상 예방 및 간 기능 개선을위한 정향 추출물 함유 기능성식품 | |
Beegum et al. | Perspectives on the cardioprotective, neuroprotective and anti-obesity functions of coconut (Cocos nucifera L.) | |
KR101886314B1 (ko) | 도화 및 마름 복합 추출물을 포함하는 비만 및 대사성 질환의 예방, 개선 또는 치료용 조성물 | |
JP6161152B2 (ja) | 脂肪肝抑制剤 | |
Abd El-Ghany et al. | Anti-diabetic effect of some herbs and fruit against streptozotocin induced diabetic rats | |
KR102488212B1 (ko) | 혈당을 개선할 수 있는 와송·여주 복합추출물 및 이의 제조방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140819 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20150203 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20150512 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160705 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20160705 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20161028 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6101888 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |